Selective androgen receptor modulator

Enobosarm

Sponsor-reported lean-mass preservation makes it a major watchlist therapy - but the evidence label matters.

Evidence Maturity · M3 - Clinical Investigational
Evidence reviewed: September 19, 2026Source-labeled

Signal summary

Enobosarm is important because its obesity-development thesis directly targets tissue quality and function in older adults using GLP-1 therapy.

Signal interpretation: QUALITY findings are sponsor-reported; publication, replication and long-term safety remain important.

Study details

Doses studied — not a dosing recommendation. Regimens belong to the named study, formulation and population.

PLATEAU registered phase 2b trial

Population
Older adults receiving semaglutide; ongoing registered trial.
Doses and administration studied
Oral enobosarm 3 mg once daily plus subcutaneous semaglutide, compared with semaglutide plus placebo.
Duration
Registered treatment period: 476 days
Reported finding / status
This is a registered regimen, not a result. The separate QUALITY findings summarized above are sponsor-reported.
Interpretation and limitations
Do not transfer outcomes from QUALITY to PLATEAU or treat trial registration as confirmation of efficacy.

Source tier D · Read the original study or record

Outcome Evidence Strength

Weight change2/5
Fat-mass change2/5
Lean-mass change2/5
Strength / function benefit2/5

Scores reflect the separately cited sponsor QUALITY report, not PLATEAU registration. Highest-strength ratings require published and replicated outcome evidence.

Editorial evidence ratings for the cited outcomes, not effect size or treatment recommendations. A lean-mass score may describe loss. 0 means not established in the reviewed evidence, not proof of no effect. Read the rubric.

What is actually established?

  • Veru reports that the Phase 2b QUALITY study met its primary endpoint for lean-mass preservation at 16 weeks in older adults receiving semaglutide.
  • The company reported greater fat loss with enobosarm plus semaglutide and a lower proportion of participants with major stair-climb-power decline.
  • The ongoing PLATEAU Phase 2b study is testing total weight, fat mass, lean mass, physical function and bone-related endpoints.

What is not established?

  • The most striking QUALITY figures are sponsor-reported and not yet equivalent to peer-reviewed pivotal evidence.
  • PLATEAU is still underway, so durability and broader clinical meaning remain open questions.
  • Body-composition effects and long-term safety must be assessed separately.

Evidence sources

A = regulatory/official • B = peer-reviewed randomized/meta-analysis • C = peer-reviewed review/observational • D = registered trial • E = sponsor-reported • F = preclinical

Source tier E: SEC filing / sponsor-reported results
QUALITY results and PLATEAU update
Source tier D: Registered Phase 2b trial
PLATEAU study record
Educational use only. This page summarizes research evidence and regulatory status. Study doses describe research, not prescribing instructions. This page does not provide personalized dosing, self-use protocols, sourcing, or a recommendation to use this therapy.